PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME

被引：1
|
作者：
Cirillo, M. [1 ,2 ]
Carnley, B. [1 ,2 ]
Tan, P. [1 ]
Tan, D. [2 ]
Sturm, M. [2 ,3 ]
机构：
[1] Royal Perth Hosp, Haematol, Perth, WA, Australia
[2] Royal Perth Hosp, Cell & Tissue Therapies, Perth, WA, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
来源：
CYTOTHERAPY | 2018年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.jcyt.2018.02.078
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
80
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    [J]. CYTOTHERAPY, 2024, 26 (06) : S40 - S40
  • [2] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    [J]. HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [3] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    [J]. BLOOD, 2014, 124 (21)
  • [4] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [5] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [6] The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome
    Papadaki, H.
    Mavroudi, I.
    Psyllaki, M.
    Pyrovolaki, K.
    Papadaki, V.
    Kalpadakis, C.
    Mastrodimou, S.
    Kaparou, M.
    Kanellou, P.
    Gvazava, G.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S47 - S48
  • [7] Improved survival rates with continued treatment with hypomethylating agents in patients with myelodysplastic syndrome in IPSS low and intermediate-1
    Moon, J.
    Sohn, S. K.
    Kim, Y. K.
    Kim, H. J.
    Lim, S. N.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. S.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Jo, D. Y.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S165 - S166
  • [8] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [9] CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE
    Oliva, E.
    Lauseker, M.
    Spiriti, M. A. Aloe
    Poloni, A.
    Cortelezzi, A.
    Palumbo, G.
    Balleari, E.
    Sanpaolo, G.
    Volpe, A.
    Ricco, A.
    Ronco, F.
    Alati, C.
    Santacaterina, I.
    Kuendgen, A.
    Germing, U.
    Latagliata, R.
    [J]. HAEMATOLOGICA, 2014, 99 : 517 - 517
  • [10] Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload
    Ivars, David
    Collado, Rosa
    Alguero, Carmen
    Carmen Tormos, M.
    Diaz, Laura
    Luis Garcia-Ghnenez, Jose
    Arrizabalaga, Beatriz
    Orero, Mayte
    Perez, Pedro
    Sanchez, Magdalena
    Angeles Ruiz, M.
    Yaguee, Nuria
    Sancho-Tello, Reyes
    Regadera, Ana
    Tormo, Mar
    Egea, Mercedes
    Vidal, Elena
    Enrique O'Connor, J.
    Saez, Guillermo T.
    Carbonell, Felix
    [J]. BLOOD, 2012, 120 (21)
12345